Prevalence of subclinical hyperthyroidism and relationship between thyroid hormonal status and thyroid ultrasonographic parameters in patients with non-toxic nodular goitre
- PMID: 8348708
- DOI: 10.1111/j.1365-2265.1993.tb01752.x
Prevalence of subclinical hyperthyroidism and relationship between thyroid hormonal status and thyroid ultrasonographic parameters in patients with non-toxic nodular goitre
Abstract
Objective: Basal plasma T4, T3 and TSH concentrations are usually normal in patients presenting with non-toxic nodular goitre. Using the evaluation of TSH response to TRH in a large series of such patients living in an area with normal iodine intake, we evaluated the prevalence of subclinical hyperthyroidism and the relationship between thyroid hormonal status and ultrasonographic parameters.
Patients: A prospective study of 242 consecutive patients (group I), referred with non-autoimmune nodular goitre, normal plasma free T4, total T3 and TSH levels, without (subgroup IA, 222 patients) or with (subgroup IB, 20 patients) clear-cut autonomous area(s) on scintigraphy. These patients were compared to 135 controls (group II).
Measurements: Plasma free T4 (FT4), total T3 (T3T) and TSH measurements. Evaluation of TSH response to TRH (delta level of increased TSH = peak TSH level during TRH test-basal TSH level), thyroid scintigraphy and morphological characteristics (number and total volume of nodule(s) and volume of extranodular tissue) determined by ultrasonography.
Results: In subgroup IA, (1) the mean (+/- SEM) basal TSH level (0.94 +/- 0.04 mU/I) and the mean value of increased TSH after TRH (4.92 +/- 0.34 mU/I) were lower (P < 0.001) than in group II (1.28 +/- 0.05 mU/I and 7.24 +/- 0.25 mU/I, respectively). The prevalence of SH (delta level of increased TSH below the mean -3 SD in controls) was 17.2%; (2) the mean FT4 level and the mean T3T value were not different (P > 0.05) from those of group II. In subgroup IB, (1) the mean basal TSH level (0.57 +/- 0.11 mU/I) and the mean increment of TSH after TRH (2.81 +/- 0.62 mU/I) were lower (P < 0.001) than in subgroup IA. The prevalence of subclinical hyperthyroidism was 75.0%; (2) the mean FT4 level (17.2 +/- 0.9 pmol/I) was not different from that in group II. However, the mean T3T value (1.99 +/- 0.01 nmol/I) was higher (P < 0.001) than in group II (1.65 +/- 0.05). In group I, subgroup IA and IB, there were significant (P < 0.05, at least) correlations between the numbers of nodules and both basal TSH levels and delta values of increased TSH or FT4 levels or T3T values. No correlations were found between other ultrasonographic data and plasma thyroid parameters.
Conclusions: This study demonstrates a high prevalence of subclinical hyperthyroidism in patients presenting with non-toxic nodular goitres and suggests that the number of nodules, but not their total volume, is an important factor in the development of this condition.
Similar articles
-
Comparison between TRH-stimulated TSH and basal TSH measurement by a commercial immunoradiometric assay in the management of thyroid disease.Q J Nucl Med. 1996 Jun;40(2):182-7. Q J Nucl Med. 1996. PMID: 8909104
-
The lack of nocturnal serum thyrotropin surge in patients with nontoxic nodular goiter may predict the subsequent occurrence of hyperthyroidism.J Clin Endocrinol Metab. 1991 Sep;73(3):604-8. doi: 10.1210/jcem-73-3-604. J Clin Endocrinol Metab. 1991. PMID: 1874936
-
Administration of a single dose of recombinant human thyrotrophin enhances the efficacy of radioiodine treatment of large compressive multinodular goitres.Clin Endocrinol (Oxf). 2004 Mar;60(3):300-8. doi: 10.1046/j.1365-2265.2003.01918.x. Clin Endocrinol (Oxf). 2004. PMID: 15008994 Clinical Trial.
-
Managing thyroid disease in general practice.Med J Aust. 2016 Aug 15;205(4):179-84. doi: 10.5694/mja16.00545. Med J Aust. 2016. PMID: 27510349 Review.
-
Hyperthyroidism: aetiology, pathogenesis, diagnosis, management, complications, and prognosis.Lancet Diabetes Endocrinol. 2023 Apr;11(4):282-298. doi: 10.1016/S2213-8587(23)00005-0. Epub 2023 Feb 24. Lancet Diabetes Endocrinol. 2023. PMID: 36848916 Review.
Cited by
-
Subclinical thyroid disease.Postgrad Med J. 1996 Mar;72(845):141-6. doi: 10.1136/pgmj.72.845.141. Postgrad Med J. 1996. PMID: 8731703 Free PMC article. Review.
-
Subclinical Graves' disease as a cause of subnormal TSH levels in euthyroid subjects.J Endocrinol Invest. 1997 Apr;20(4):183-8. doi: 10.1007/BF03346900. J Endocrinol Invest. 1997. PMID: 9211123
-
Which Is the Ideal Treatment for Benign Diffuse and Multinodular Non-Toxic Goiters?Front Endocrinol (Lausanne). 2016 May 23;7:48. doi: 10.3389/fendo.2016.00048. eCollection 2016. Front Endocrinol (Lausanne). 2016. PMID: 27242669 Free PMC article. Review.
-
Long-Term Effects of 0.1 mg Recombinant-Human-Thyrotropin-Stimulated Fixed-Dose Radioiodine Therapy in Patients with Recurrent Multinodular Goiter after Surgery.Diagnostics (Basel). 2024 Apr 30;14(9):946. doi: 10.3390/diagnostics14090946. Diagnostics (Basel). 2024. PMID: 38732360 Free PMC article.
-
Management of Retrosternal Goiter in Resource-Limited Settings: Outcomes From 28 Cases Using Cervical Approach.Cureus. 2023 Jul 2;15(7):e41288. doi: 10.7759/cureus.41288. eCollection 2023 Jul. Cureus. 2023. PMID: 37539408 Free PMC article.
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Medical
Research Materials